This program is derived from a lecture delivered at the 2023 Eastern Pulmonary Conference. The expert faculty, Drs. Reynold A. Panettieri Jr. and Anne E. O’Donnell, will highlight recent advances in the treatment and management of patients with non-tuberculous mycobacterial lung disease. The faculty will utilize a case-based approach to analyze current clinical trial data of amikacin-based inhalation therapeutics for the treatment of NTM-LD. Best practices for developing guideline-driven individualized treatment plans to improve outcomes and quality of life for patients with NTM-LD will be relayed in an interactive panel format.
Pulmonologists and other HCPs who care for patients with NTM-LD
- Review NTM-LD pathophysiology associated patient risk factors/signs/symptoms, underlying conditions including bronchiectasis, and strategies for early and accurate diagnosis
- Analyze clinical trial data of amikacin-based inhalation therapeutics for the treatment of NTM-LD
- Develop guideline-driven individualized treatment plans coordinating anti-microbial therapy with respiratory therapy to improve outcomes for patients with NTM-LD
I. NTM-LD Update: Risk Factors, Accurate Diagnosis, and Comorbidities
II. Clinical Trial Analysis of Amikacin-Based Inhalation Therapeutics for the Treatment of NTM-LD
III. Challenging Patient Case Presentations – Guideline-Driven Individualized Treatment Plans to Improve Outcomes for Patients with NTM-LD
Reynold A. Panettieri, Jr., MD (Course Chair)
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
Emeritus Professor of Medicine, University of Pennsylvania
New Brunswick, NJ
Anne E. O’Donnell, MD
Nehemiah and Naomi Cohen Chair, Pulmonary Disease Research
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Georgetown University Hospital
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Reynold A. Panettieri Jr., MD||Consultant/Advisor: AstraZeneca; Genentech, Inc.; Praesidia Biotherapeutics Inc.; RIFM; Teva Pharmaceutical Industries Ltd.
Research/Grant Support: ACTIV-1; Agomab Therapeutics; AstraZeneca; Janssen Pharmaceuticals; Medimmune; RIFM; Teva Pharmaceutical Industries Ltd.; Vault Health
Speaker’s Bureau: AstraZeneca; Merck Corporation; Sanofi
|Anne E. O’Donnell, MD||Consultant/Advisor: Boehringer Ingelheim International GmbH; Insmed; Paratek Pharmaceuticals
Research/Grant Support: AN2 Therapeutics; Boehringer Ingelheim International GmbH; Insmed; Paratek Pharmaceuticals; RedHill Biopharma Ltd.
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
Physcians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Insmed.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Insmed do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].